✦ LIBER ✦

HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis

✍ Scribed by A. S. RAMCHARAN; K. J. VAN STRALEN; J. D. SNOEP; A. K. MANTEL-TEEUWISSE; F. R. ROSENDAAL; C. J. M. DOGGEN

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HMG CoA reductase inhibitors and the ris

✍ C. J. M. Doggen; R. N. Lemaitre; N. L. Smith; S. R. Heckbert; B. M. Psaty 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Economics of lipid lowering with HMG CoA

✍ D. Roger Illingworth 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

Myopathy/rhabdomyolysis in patients afte

✍ U.P. Ketelsen; D. Trenk; E.M. Eschenbruch; P.J. Tollenaere 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 135 KB

Lipid-lowering drugs in the MPTP mouse m

✍ Alexandre Kreisler; Patrick Gelé; Jean-François Wiart; Michel Lhermitte; Alain D 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 828 KB

A HMG-CoA reductase inhibitor possesses

✍ Daigo Sumi; Toshio Hayashi; Navin Kumar Thakur; Muthuvel Jayachandran; Yukako As 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 277 KB